Multisystem inflammatory syndrome in children: Another COVID-19 sequel
Loading...
Files
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Cambridge University Press
Abstract
With the rapid expansion of the COVID-19 pandemic, the disease burden and its consequences on the paediatric population has been progressively recognised. Although COVID-19 infection in children presents as asymptomatic to mild illness, instances of hyperinflammation and multi-organ involvement following the viral infection have been described. This condition, known as the multisystem inflammatory syndrome in children (MIS-C), has gained a wide global attention. Despite the global efforts to uncover the disease characteristics and management, a clear pathogenesis and a unified treatment regimen have not been reached yet. This paper tackles the epidemiology of the MIS-C, discusses its suggested pathogenesis, drives through its varying clinical presentations, and evaluates the different treatment regimens employed in managing MIS-C. © The Author(s), 2023. Published by Cambridge University Press.
Description
Keywords
Coronavirus, Covid-19, Multisystem inflammatory syndrome in children, Child, Connective tissue diseases, Humans, Pandemics, Pediatric multisystem inflammatory disease, covid-19 related, Systemic inflammatory response syndrome, Anakinra, Antibiotic agent, Dobutamine, Epinephrine, Glucocorticoid, Heparin, Immunoglobulin, Infliximab, Inotropic agent, Methylprednisolone, Noradrenalin, Artificial ventilation, Bacterial infection, Clinical feature, Comorbidity, Coronary artery thrombosis, Coronavirus disease 2019, Disease predisposition, Epidemiological data, Extracorporeal oxygenation, Heart left ventricle thrombosis, Hemodynamics, Human, Hydration, Intensive care, Mucocutaneous lymph node syndrome, Oxygen therapy, Pathogenesis, Patient care, Practice guideline, Prognosis, Review, Shock, Thrombosis, Toxic shock syndrome, Connective tissue disease, Pandemic